Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vibeke Strand

Showing results (271-280 of 435) with videos related to

Pageof 44
Sort By:
Annals of the Rheumatic Diseases|May 8, 2010
Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritisJeremy Sokolove, Vibeke Strand, Jeffrey D Greenberg, et al.
Arthritis Research & Therapy|September 8, 2016
Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trialVibeke Strand, Mark Kosinski, Chieh-I Chen, et al.
Arthritis Research & Therapy|September 11, 2015
Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patientsJosef S Smolen, Ronald van Vollenhoven, Arthur Kavanaugh, et al.
RMD Open|March 23, 2023
Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extensionLihi Eder, Dafna D Gladman, Philip Mease, et al.
The New England Journal of Medicine|April 22, 2005
Leflunomide or methotrexate for juvenile rheumatoid arthritisEarl Silverman, Richard Mouy, Lynn Spiegel, et al.
The Journal of Rheumatology|April 3, 2016
Ms. A.M. Taylor, et al replyAnn M Taylor, Justin O Taylor, Jasvinder A Singh, et al.
RMD Open|July 21, 2022
Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trialPhilip S Helliwell, Phillip J Mease, Arthur Kavanaugh, et al.
Rheumatology (Oxford, England)|July 14, 2023
The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory goutHerbert S B Baraf, Puja P Khanna, Alan J Kivitz, et al.
RMD Open|February 5, 2019
Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL BeyondVibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, et al.
Lupus Science & Medicine|August 25, 2022
Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE with lupus nephritis (LN)Rebecca Williams-Hall, Pamela Berry, Nicola Williamson, et al.
Pageof 44

Showing results (271-280 of 435) with videos related to

Sort By:
Pageof 44
Annals of the Rheumatic Diseases|May 8, 2010
Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritisJeremy Sokolove, Vibeke Strand, Jeffrey D Greenberg, et al.
Arthritis Research & Therapy|September 8, 2016
Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trialVibeke Strand, Mark Kosinski, Chieh-I Chen, et al.
Arthritis Research & Therapy|September 11, 2015
Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patientsJosef S Smolen, Ronald van Vollenhoven, Arthur Kavanaugh, et al.
RMD Open|March 23, 2023
Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extensionLihi Eder, Dafna D Gladman, Philip Mease, et al.
The New England Journal of Medicine|April 22, 2005
Leflunomide or methotrexate for juvenile rheumatoid arthritisEarl Silverman, Richard Mouy, Lynn Spiegel, et al.
The Journal of Rheumatology|April 3, 2016
Ms. A.M. Taylor, et al replyAnn M Taylor, Justin O Taylor, Jasvinder A Singh, et al.
RMD Open|July 21, 2022
Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trialPhilip S Helliwell, Phillip J Mease, Arthur Kavanaugh, et al.
Rheumatology (Oxford, England)|July 14, 2023
The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory goutHerbert S B Baraf, Puja P Khanna, Alan J Kivitz, et al.
RMD Open|February 5, 2019
Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL BeyondVibeke Strand, Kurt de Vlam, Jose A Covarrubias-Cobos, et al.
Lupus Science & Medicine|August 25, 2022
Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE with lupus nephritis (LN)Rebecca Williams-Hall, Pamela Berry, Nicola Williamson, et al.
Pageof 44